<DOC>
	<DOCNO>NCT00290732</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy different way , breast duct , may kill tumor cell . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase I trial study side effect best dose liposomal doxorubicin give mastectomy treat woman invasive breast cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Before Mastectomy Treating Women With Invasive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate feasibility , safety , maximum tolerate dose intraductal pegylated doxorubicin HCl liposome woman invasive breast cancer await mastectomy . Secondary - Determine pharmacokinetics intraductal pegylated doxorubicin HCl liposome , include serial plasma concentration doxorubicin doxorubicinol tissue concentration different portion breast time surgery . OUTLINE : This dose-escalation study . Patients receive intraductal injection pegylated doxorubicin HCl liposome* day 1 . Patients undergo mastectomy 2-4 week later . Cohorts 3-6 patient receive escalate dos pegylated doxorubicin HCl liposome* maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . NOTE : *The first cohort 3 patient receive intraductal dextrose follow surgery feasibility study . An additional 3 patient receive intravenous PLD enrol pharmacokinetic control portion study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm infiltrate carcinoma breast meeting follow criterion : T13 , N disease Proven ductal carcinoma situ Unresected disease Planned mastectomy definitive surgical procedure Known suspect metastatic disease allow provide mastectomy plan Nonpalpable tumor allow ( e.g. , initial T23 tumor respond preoperative therapy ) No inflammatory breast cancer T4 feature Successful baseline ductogram Baseline nipple aspiration procedure must identify duct productive nipple aspirate fluid No severe nipple retraction Hormone receptor status specify PATIENT CHARACTERISTICS : Female patient Menopausal status specify ECOG performance status 02 Absolute neutrophil count ≥1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 2 time upper limit normal ( ULN ) Bilirubin ≤ 2 time ULN AST ALT ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant history severe allergy iodinate contrast material debilitate anxiety may allow ductogram PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior preoperative chemotherapy , trastuzumab ( Herceptin® ) , hormonal therapy allow provide complete 714 day prior study treatment No prior radiation therapy , excisional biopsy , breast reduction , areolar surgery , breast implant ( present past history implant remove ) No prior procedure may alter breast ductal system ipsilateral breast No concurrent chemotherapy , radiotherapy , endocrine therapy , biologic agent breast cancer No concurrent investigational drug Concurrent bisphosphonates allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>